Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,totalCashflowsFromInvestingActivities,capitalExpenditures,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,ETON,21018000.0,24507600,877000,,5116000,,5116000,4067000,10307000,5363000,5363000,,-266000,,,,0,11897000,6534000,1590000,-247000,,5116000,5116000,537000.0,108573000.0,9631000.0,21555000.0,31186000.0,24000.0,551000.0,-87042000.0,36000.0,25113000.0,3199000.0,726000.0,339000.0,30274000.0,300000.0,6353000.0,1348000.0,1761000.0,-583000.0,103000.0,-1324000.0,103000.0,3818000.0,3715000.0,155000.0,-106000.0,-252000.0,673000.0,,,,27075000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,1.1899996,0.29528525,4.03 - 10.3,-5.0800004,-0.4932039,4.03,10.3,1620936000,1636405200,1637010000,-0.613,0.26,0.17,-0.9487702,5.21 - 5.32,5.27,5.21,5.24,10,11,finmb_435353222,NasdaqGM,"Eton Pharmaceuticals, Inc.",USD,729837,284966,30.705881,0.88,5.173611,0.046388626,0.008966392,6.9363046,-1.7163048,-0.24743792,127929664,20.076923,5.931818,15,America/New_York,EDT,-14400000,2,NGM,REGULAR,us_market,"Eton Pharmaceuticals, Inc.",5.22,1630510606,-0.05000019,5.3,5.32,5.21,44360,1.26,,,10.3,4.03,5.17,6.94,729.84k,284.97k,24.51M,,16.49M,17.78%,34.37%,1.48M,3.33,7.52%,6.02%,1.42M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-116.63%,-108.70%,-33.21%,-85.81%,11.84M,0.52,"11,917.20%",-247k,-12.35M,-13.8M,-0.61,,25.11M,1.02,7.32M,33.94,9.46,0.88,-11.41M,-6.8M,Value,60010-7208,Healthcare,16,8,8,"Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.",Deer Park,847 787 7361,IL,8,1609372800,1622505600,9,United States,http://www.etonpharma.com,86400,9,21925 West Field Parkway,510 937 0262,Biotechnology,Suite 235
t-1,ETON,15088000.0,24507600,3387000,,-7687000,,-7687000,3814000,-219000,-7420000,-7420000,,-269000,,,,0,81000,7501000,300000,-267000,,-7687000,-7687000,575000.0,107797000.0,10656000.0,15663000.0,26319000.0,24000.0,,-92158000.0,40000.0,21295000.0,3794000.0,280000.0,1003000.0,24701000.0,48000.0,6763000.0,1242000.0,2344000.0,136000.0,21189000.0,-1010000.0,21189000.0,13963000.0,-7182000.0,161000.0,457000.0,-48000.0,773000.0,-44000.0,-44000.0,,20907000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,1.1899996,0.29528525,4.03 - 10.3,-5.0800004,-0.4932039,4.03,10.3,1620936000,1636405200,1637010000,-0.613,0.26,0.17,-0.9487702,5.21 - 5.32,5.27,5.21,5.24,10,11,finmb_435353222,NasdaqGM,"Eton Pharmaceuticals, Inc.",USD,729837,284966,30.705881,0.88,5.173611,0.046388626,0.008966392,6.9363046,-1.7163048,-0.24743792,127929664,20.076923,5.931818,15,America/New_York,EDT,-14400000,2,NGM,REGULAR,us_market,"Eton Pharmaceuticals, Inc.",5.22,1630510606,-0.05000019,5.3,5.32,5.21,44360,1.26,,,10.3,4.03,5.17,6.94,729.84k,284.97k,24.51M,,16.49M,17.78%,34.37%,1.48M,3.33,7.52%,6.02%,1.42M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-116.63%,-108.70%,-33.21%,-85.81%,11.84M,0.52,"11,917.20%",-247k,-12.35M,-13.8M,-0.61,,25.11M,1.02,7.32M,33.94,9.46,0.88,-11.41M,-6.8M,Value,60010-7208,Healthcare,16,8,8,"Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.",Deer Park,847 787 7361,IL,8,1609372800,1622505600,9,United States,http://www.etonpharma.com,86400,9,21925 West Field Parkway,510 937 0262,Biotechnology,Suite 235
t-2,ETON,776000.0,24507600,2813000,,-6504000,,-6504000,3442000,-17000,-6272000,-6272000,,-232000,,,,0,-161000,6111000,-144000,-232000,,-6504000,-6504000,612000.0,85838000.0,10007000.0,1388000.0,11395000.0,21000.0,,-84471000.0,81000.0,7332000.0,3219000.0,219000.0,917000.0,9785000.0,,6788000.0,1699000.0,2208000.0,255000.0,2158000.0,222000.0,43000.0,-2938000.0,-5094000.0,164000.0,10000.0,-48000.0,724000.0,-2000.0,-2000.0,2115000.0,6566000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,1.1899996,0.29528525,4.03 - 10.3,-5.0800004,-0.4932039,4.03,10.3,1620936000,1636405200,1637010000,-0.613,0.26,0.17,-0.9487702,5.21 - 5.32,5.27,5.21,5.24,10,11,finmb_435353222,NasdaqGM,"Eton Pharmaceuticals, Inc.",USD,729837,284966,30.705881,0.88,5.173611,0.046388626,0.008966392,6.9363046,-1.7163048,-0.24743792,127929664,20.076923,5.931818,15,America/New_York,EDT,-14400000,2,NGM,REGULAR,us_market,"Eton Pharmaceuticals, Inc.",5.22,1630510606,-0.05000019,5.3,5.32,5.21,44360,1.26,,,10.3,4.03,5.17,6.94,729.84k,284.97k,24.51M,,16.49M,17.78%,34.37%,1.48M,3.33,7.52%,6.02%,1.42M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-116.63%,-108.70%,-33.21%,-85.81%,11.84M,0.52,"11,917.20%",-247k,-12.35M,-13.8M,-0.61,,25.11M,1.02,7.32M,33.94,9.46,0.88,-11.41M,-6.8M,Value,60010-7208,Healthcare,16,8,8,"Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.",Deer Park,847 787 7361,IL,8,1609372800,1622505600,9,United States,http://www.etonpharma.com,86400,9,21925 West Field Parkway,510 937 0262,Biotechnology,Suite 235
t-3,ETON,6381000.0,24507600,1595000,,-4730000,,-4730000,2935000,-8000,-4538000,-4538000,,-192000,,,,0,20000,4558000,28000,-192000,,-4730000,-4730000,650000.0,84977000.0,7528000.0,7031000.0,14559000.0,21000.0,,-77967000.0,52000.0,10270000.0,2739000.0,159000.0,1034000.0,12823000.0,,4789000.0,1709000.0,1953000.0,770000.0,788000.0,-16000.0,427000.0,-2065000.0,-2853000.0,164000.0,17000.0,205000.0,714000.0,-2000.0,-2000.0,361000.0,10084000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,1.1899996,0.29528525,4.03 - 10.3,-5.0800004,-0.4932039,4.03,10.3,1620936000,1636405200,1637010000,-0.613,0.26,0.17,-0.9487702,5.21 - 5.32,5.27,5.21,5.24,10,11,finmb_435353222,NasdaqGM,"Eton Pharmaceuticals, Inc.",USD,729837,284966,30.705881,0.88,5.173611,0.046388626,0.008966392,6.9363046,-1.7163048,-0.24743792,127929664,20.076923,5.931818,15,America/New_York,EDT,-14400000,2,NGM,REGULAR,us_market,"Eton Pharmaceuticals, Inc.",5.22,1630510606,-0.05000019,5.3,5.32,5.21,44360,1.26,,,10.3,4.03,5.17,6.94,729.84k,284.97k,24.51M,,16.49M,17.78%,34.37%,1.48M,3.33,7.52%,6.02%,1.42M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-116.63%,-108.70%,-33.21%,-85.81%,11.84M,0.52,"11,917.20%",-247k,-12.35M,-13.8M,-0.61,,25.11M,1.02,7.32M,33.94,9.46,0.88,-11.41M,-6.8M,Value,60010-7208,Healthcare,16,8,8,"Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.",Deer Park,847 787 7361,IL,8,1609372800,1622505600,9,United States,http://www.etonpharma.com,86400,9,21925 West Field Parkway,510 937 0262,Biotechnology,Suite 235
